UniQure NV’s stock plummeted over 54% after the FDA deemed the clinical data for its Huntington’s disease gene therapy AMT-130 inadequate. Investors are left questioning the future of the therapy and …
UniQure stock crashes over 50% today after FDA says Huntington’s therapy data isn’t enough – here’s what investors need to know
view original post